馬勝林，男，西湖大學醫學院教授，杭州市第一人民醫院腫瘤放療科主任醫師，博士生導師、博士後導師。現任杭州市衛生和計畫生育委員會黨委委員，杭州市第一人民醫院集團管理委員會主任。浙江省“新世紀151人才工程”第一層次，浙江省衛生領軍人才，浙江省有突出貢獻中青年專家，浙江省優秀院長，杭州市傑出人才，杭州市成績突出科技工作者，享受國務院政府特殊津貼。
馬勝林從事惡性腫瘤診治近40年，致力於胸腹部惡性腫瘤放療、化療、熱療等綜合治療基礎與臨床轉化研究，尤其是對中晚期疑難惡性腫瘤有獨特的的創新見解。近年來承擔國家863課題、國家新藥創製、國家自然科學基金、浙江省自然科學基金重點項目、省部共建項目等10餘項，主編/副主編專著13部，獲教育部工程技術研究成果獎一等獎等省部級及市級科技進步獎項10餘項，國家發明專利8項。
基本介紹
人物簡介,擅長領域,人物經歷,研究方向,課題項目,主要成就,制定共識,發表論著,發明專利,代表論文,人才培養,學術任職,出診時間,獎項榮譽,
人物簡介
馬勝林，主任醫師、教授、博士生導師。獲評為浙江省“新世紀151人才工程”第一層次，浙江省衛生領軍人才，浙江省有突出貢獻中青年專家，中國優秀院長，杭州市B類高層次人才（享受國務院特殊津貼），杭州市高峰學科腫瘤學學科帶頭人等。曾任浙江省腫瘤醫院副院長。
從事惡性腫瘤診治近40年，致力於胸腹部惡性腫瘤放療、化療、熱療等綜合治療基礎與臨床轉化研究，尤其對中晚期疑難惡性腫瘤診療有獨特的創新見解。近年來承擔國家863課題、國家新藥創製、國家自然科學基金、浙江省自然科學基金重點項目、省部共建項目等10餘項，主編/副主編專著13部，獲省市級科技進步獎項10餘項，國家發明專利8項。
以第一作者或通訊作者在 Cell Research, Nature Communications, Neurooncology, Cancer Letters, Cancer Communications, Acta Pharmacol Sin, International Journal of Cancer, Lung Cancer, Journal of Translational Cancer 等國際知名雜誌發表 SCI 論文150 余篇。
牽頭制定《中國腫瘤熱療臨床套用指南》《腫瘤熱療中國專家共識》《 “肺癌診療一體化模式”浙江省專家共識》《浙江省非小細胞肺癌血液EGFR基因突變檢測專家共識》《NSCLC HER2變異檢測全國專家共識》共5部，參與制定《Ⅲ期非小細胞肺癌多學科診療專家共識（2019版）》《NTRK基因融合實體瘤診治中國共識》《胸腺瘤診治中國共識》《胸膜間皮瘤診治中國共識》等多項指南或共識，其中英文版5部。
擅長領域
從事惡性腫瘤的綜合治療30餘年，尤其在胸腹部惡性腫瘤（肺癌、胰腺癌等）的放療、化療、熱療、生物治療、中西醫結合治療、個體化治療等非手術綜合治療基礎與臨床研究方面有很深的造詣。
人物經歷
1987.08-1992.12，浙江省腫瘤醫院 住院醫師 (腫瘤學)
1993.01-1999.07，浙江省腫瘤醫院 主治醫師 副主任醫師 科副主任/主任 (腫瘤學)
1999.07-2011.01，浙江省腫瘤醫院 副院長 主任醫師
2011.01-2020.07，杭州市第一人民醫院院長 杭州市第一人民醫院集團管委會主任 主任醫師
2020.07-2020.12，杭州市第一人民醫院吳山院區 杭州市腫瘤醫院 黨委書記 主任醫師
2020.12-2026.01，杭州市第一人民醫院吳山院區 首席專家 主任醫師
2026.01至今， 西湖大學教授
研究方向
腫瘤放射治療為基礎的綜合治療臨床與轉化研究
腫瘤熱療的臨床與轉化研究
抗腫瘤藥物藥理與毒理的臨床與轉化研究
課題項目
近年來主持國家"863"計畫子課題、國家新藥創製項目、國家自然科學基金面上項目、省自然科學基金重點項目、省中醫藥科技計畫重大項目等10餘項。
主要成就
制定共識
牽頭制定《中國腫瘤熱療臨床套用指南》,《腫瘤熱療中國專家共識》, “肺癌診療一體化模式”浙江省專家共識， 《浙江省非小細胞肺癌血液EGFR基因突變檢測專家共識》，《二代測序技術再腫瘤精準醫學診斷套用專家共識》，NSCLC HER2變異檢測全國專家共識共7部，參與Ⅲ期非小細胞肺癌多學科診療專家共識（2019版），NTRK基因融合實體瘤診治中國共識，胸腺瘤診治中國共識，胸膜間皮瘤診治中國共識等多項，其中英文版5部。
發表論著
發表SCI論文100餘篇。主編、副主編專著13部。
發明專利
獲國家發明專利8項，多項研究成果居國內、國際領先。
代表論文
1.Huang J, Qian J, Zhong Y, Xia B, Feng X, Meng W, Wei D, Liang J, Ding Y, Xu R, Xiang J, Jiang H, Ma S, Chen X. Development of a machine learning-based model to predict prognosis of resected invasive pulmonary adenocarcinoma. J Thorac Dis. 2025 Dec 31;17(12):11057-11067.
2.Gao W, Liang J, Wang L, Zhao Y, Ma S, Zhu L. Hyperthermia correlates with low incidence of radiation pneumonitis after thoracic radiotherapy: a retrospective study. BMC Cancer. 2025 Nov 8;25(1):1731.
3.Pan K, Wang B, Xu X, Tang Y, Liang J, Ma S, Xia B, Zhu L. Efficacy analysis of brain radiotherapy in EGFR mutation non-small cell lung cancer with brain metastasis: a retrospective study. Discov Oncol. 2025 Apr 8;16(1):488.
4.Zhang S, He S, Zhu X, Wang Y, Xie Q, Song X, Xu C, Wang W, Xing L, Xia C, Wang Q, Li W, Zhang X, Yu J, Ma S, Shi J, Gu H. DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues. Nat Commun. 2023 Sep 14;14(1):5686.
5.Zhao Y, Gu S, Li L, Zhao R, Xie S, Zhang J, Zhou R, Tu L, Jiang L, Zhang S, Ma S. A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma. Neuro Oncol. 2023 Dec 8;25(12):2207-2220.
6.Luo P, Yan H, Chen X, Zhang Y, Zhao Z, Cao J, Zhu Y, Du J, Xu Z, Zhang X, Zeng S, Yang B, Ma S, He Q. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res. 2020 Sep;30(9):779-793.
7.Deng G, Wang R, Sun Y, Huang CP, Yeh S, You B, Feng C, Li G, Ma S, Chang C. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Cell Death Differ. 2021 Jul;28(7):2145-2159.
8.Zhang S, Zhu L, Xia B, Chen E, Zhao Q, Zhang X, Chen X, Chen X, Ma S. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Commun (Lond). 2018 May 22;38(1):28.
9.Zhang H, Jiang H, Zhu L, Li J, Ma S. Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives. Cancer Lett. 2021 Aug 28;514:38-47.
10.Zhang J, Wu Q, Zhu L, Xie S, Tu L, Yang Y, Wu K, Zhao Y, Wang Y, Xu Y, Chen X, Ma S, Zhang S. SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer. Cancer Lett. 2022 Jan 1;524:268-283.
11.中國臨床腫瘤學會腫瘤熱療專家委員會,中日醫學科技交流協會熱療專家委員會,中華醫學會放療分會熱療學組. 腫瘤熱療中國專家共識. 實用腫瘤雜誌,2020,35(1):1-10.
12.中日醫學科技交流協會熱療專業委員會,中華醫學會放療分會熱療專業委員會. 中國腫瘤熱療臨床套用指南(2017.V1.1). 中華放射腫瘤學雜誌,2017,26(4):369-375.
13.中國抗癌協會肺癌專業委員會,中華醫學會腫瘤學分會肺癌學組. Ⅲ期非小細胞肺癌多學科診療專家共識( 2019版). 中華腫瘤雜誌,2019,41(12):881-890.
14.Huang J, Xu Y, Chen Y, Shen J, Qiu Y, Li X, Chen X, Ma S. Revisiting the role of pregnancy zone protein (PZP) as a cancer biomarker in the immunotherapy era. J Transl Med 2024, 22(1):500.
15.Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. Acta Pharmacologica Sinica 2024, 45(6):1252-1263.
16.Wu Q, Liu X, Wang LM, Yang YH, Pan LF, Zhang JJ, Wang YQ, Yao QH, Ma SL, Zhang SR. Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response. Phytother Res. 2024 Aug;38(8):4151-4167
17.Wang Y, Luo J, Bai M, Ma Z, Xu Y, Liu D, Jiang H, Ma S, Zhang S. Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells. Drug Metab Dispos. 2024 Oct 16;52(11):1332-1344.
18.Xie S, Liang J, Zhao Y, Zhang J, Chen X, Jiang H, Zhang Z, Ma S, Zhang S. The second-generation tyrosine kinase inhibitor afatinib inhibits IL-1β secretion via blocking assembly of NLRP3 inflammasome independent of epidermal growth factor receptor signaling in macrophage. Mol Immunol 2023, 153:135-145.
19.Huang J, Chen X, Xia B, Ma S. Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review. Front Immunol 2023, 14:1082980.
20.Zhang J#, Pan L#, Zhang S, Yang Y, Liang J, Ma S*, Wu Q#. CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.
Clin Transl Oncol. 2023 Dec;25(12):3527-3540.
21.Zhang S#, Liu X, Hao Y, Yang H, Zhao W, Mao C*, Ma S*. Synergistic therapeutic effect of nanomotors triggered by Near-infrared light and acidic conditions of tumor. J Colloid Interface Sci. 2023, 650(Pt A):67-80.
22.Zhang H#, Zhang K#, Qiu L, Yue J, Jiang H, Deng Q, Zhou R, Yin Z, Ma S*, Ke Y*. Cancer-associated fibroblasts facilitate DNA damage repair by promoting the glycolysis in non-small cell lung cancer. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166670
23.Shengxiang Ren#, Jifeng Feng#, Shenglin Ma#, Caicun Zhou*, et al. KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. International Journal of Cancer, 2023, 153(3): 623-634.
24.Shujun Xie, Jiafeng Liang, Yanyan Zhao, Jingjing Zhang, Xueqin Chen, Hong Jiang, Zhen Zhang, Shenglin Ma, Shirong Zhang. The second-generation tyrosine kinase inhibitor afatinib inhibits IL-1β secretion via blocking assembly of NLRP3 inflammasome independent of epidermal growth factor receptor signaling in macrophage. Mol Immunol, 2023 Jan;153:135-145 .
25.Shenglin Ma. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer. Thorac Cancer. 2023 Jan;14(1):91-104 .
26.Zhang J, Zhang K, Hao Y, Yang H, Wang J, Zhang Y, Zhao W, Ma S, Mao C. Polydopamine nanomotors loaded indocyanine green and ferric ion for photothermal and photodynamic synergistic therapy of tumor. J Colloid Interface Sci. 2023 Mar;633:679-690.
27.Zhu L, Xia B, Ma S. Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out. Thorac Cancer 2022, 13(5):659-663.
28.Zhang S, Xiao X, Zhu X, Chen X, Zhang X, Xiang J, Xu R, Shao Z, Bai J, Xun Y et al. Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung Cancer. Cancers (Basel) 2022, 14(13).
29.Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S et al. Positive Correlation of Peripheral CD8(+) T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel) 2022, 14(15).
30.Shen J, Huang J, Huang Y, Chen Y, Li J, Luo P, Zhang Q, Qiu Y, Wang L, Jiang H et al. Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism. Ann Transl Med 2022, 10(24):1337.
31.Zhu L, Zou C, Zhang Z, Wang J, Yang L, Rao C, Yang Z, Liang J, Xia B, Shenglin MA. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study. BMC Cancer 2021, 21(1):511.
32.Kong W, Zhu H, Zheng S, Yin G, Yu P, Shan Y, Liu X, Ying R, Zhu H, Ma S*. Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer. J Cell Mol Med. 2022 Nov;26(21):5539-5550.
33.Feng X, Xiong X, Ma S*. Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer. Front Pharmacol. 2022 Mar 2;13:832725.
34.Kan Wu#, Bing Xia#, Jing Zhang, Xin Li, Shaoyu Yang, Minna Zhang, Lucheng Zhu, Bing Wang, Xiao Xu, Shenglin Ma *, Xueqin Chen *. Positive correlation of peripheral CD8+ T lymphocytes with immune-related adverse events and combinational prognostic value in advanced non‐small cell lung cancer patients receiving immune checkpoint inhibitors. Cancers (Basel), 2022, 14(15): 3568.
35.Shirong Zhang , Xiao Xiao, Xiuli Zhu, Xueqin Chen, Xiaochen Zhang, Jingjing Xiang, Rujun Xu, Zhuo Shao, Jing Bai, Yanping Xun, Yanping Jiang, Zhengzheng Chen, Xuefeng Xia, Hong Jiang, Shenglin Ma. Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung Cancer. Cancers (Basel). 2022 Jun 22;14(13):3061.
36.Wu K, Chen X, Feng J, Zhang S, Xu Y, Zhang J, Wu Q, You M, Xia B, Ma S. Capilliposide C from Lysimachia capillipes Restores Radiosensitivity in Ionizing Radiation-Resistant Lung Cancer Cells Through Regulation of ERRFI1/EGFR/STAT3 Signaling Pathway. Front Oncol 2021, 11:644117.
37.Wu K, Chen X, Chen X, Zhang S, Xu Y, Xia B, Ma S. Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis. J Int Med Res 2021, 49(2):300060520981545.
38.Wang Y, Huang J, Wu Q, Zhang J, Ma Z, Zhu L, Xia B, Ma S, Zhang S. Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha. Front Oncol 2021, 11:668798.
39.Pan K, Zhao L, Gu S, Tang Y, Wang J, Yu W, Zhu L, Feng Q, Su R, Xu Z et al. Deep learning-based automatic delineation of the hippocampus by MRI: geometric and dosimetric evaluation. Radiat Oncol 2021, 16(1):12.
40.Ma S, Shi M, Chen X, Wang Y, Yang Z, Lizaso A, Li M, Li H, Zhang L, Mao X et al. The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Transl Lung Cancer Res 2021, 10(1):326-339.
41.Li X, Huang J, Qiu Y, Zhang Q, Yang S, Wu K, Wang J, Wang L, Ye J, Ma S et al.Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study. Front Pharmacol 2021, 12:649222.
42.Huang J, Zhang Q, Shen J, Chen X, Ma S. Multi-omics analysis identifies potential mechanisms of AURKB in mediating poor outcome of lung adenocarcinoma. Aging (Albany NY) 2021, 13(4):5946-5966.
43.Shirong Zhang#, Yang Xu#, Shenglin Ma*. Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component. Front Oncol. 2021;11:652193.
44.Yuqing Wang#, Jie Huang, Shenglin Ma*, Shirong Zhang*. Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha. Front Oncol. 2021;11:668798.
45.Yanyan Zhao, Jing Jia, Shenglin Ma*, Shirong Zhang*.Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT. Acta Pharmacol Sin. 2021;42(8):1288-1297.
46.Hongfang Zhang #, Jingxing Si#, Jing Yue, Shenglin Ma*. The mechanisms and reversal strategies of tumor radioresistance in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2021;147(5):1275-1286.
47.Yuqing Wang, Jie Huang, Shenglin Ma*, Shirong Zhang*. Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38. Invest New Drugs. 2021;39(2):458-468.
48.Zhang SR, Zhang XC, Liang JF, Fang HM, Huang HX, Zhao YY, Chen XQ, Ma SL. Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis. Acta Pharmacologica Sinica 2020, 41(6):825-834.
49.Tang Y, Xia B, Xie R, Xu X, Zhang M, Wu K, Wang B, Ma S. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI. Lung Cancer 2020, 140:65-70.
50.Zhu L, Zhang S, Xun Y, Jiang Y, Xia B, Chen X, Wang L, Jiang H, Ma S. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment. Pathology oncology research : POR 2018, 24(4):843-851.
51.Zhang SR, Zhu LC, Jiang YP, Zhang J, Xu RJ, Xu YS, Xia B, Ma SL. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacologica Sinica 2017, 38(2):233-240.
52.Zhang SR, Xu YS, Jin E, Zhu LC, Xia B, Chen XF, Li FZ, Ma SL. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacologica Sinica 2017, 38(1):100-109.
53.Wu Z, Jing S, Li Y, Gao Y, Yu S, Li Z, Zhao Y, Piao J, Ma S, Chen X. The effects of SAHA on radiosensitivity in pancreatic cancer cells by inducing apoptosis and targeting RAD51. Biomed Pharmacother 2017, 89:705-710.
54.Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X et al. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Mol Cancer Ther 2016, 15(5):842-853.
55.Yang XP, Liu L, Wang P, Ma SL. Human Sulfatase-1 Improves the Effectiveness of Cytosine Deaminase Suicide Gene Therapy with 5-Fluorocytosine Treatment on Hepatocellular Carcinoma Cell Line HepG2 In Vitro and In Vivo. Chin Med J (Engl). 2015;128(10):1384-1390.
56.Chen X, Chen D, Yang S, et al. Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer Cell Int. 2015;15:43. Published 2015 Apr 19.
57.Shi S, Yuan C, Zhuang K, et al. Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor. Mol Med Rep. 2015;11(5):3842-3847.
58.Xu Y, Zhang Y, Ma S. EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer. 2011;73(3):249-255.
59.Deng Q, Sheng L, Su D, et al. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China. Med Oncol. 2011;28(3):667-672.
60.Fang L, Wang Z, Kong WY, Feng JG, Ma SL, Lin NM. Anti-tumor and apoptotic effects in vitro and in vivo of a traditional Chinese medicine prescription. Chin Med J (Engl). 2011;124(21):3583-3587.
61.Hua Y, Ma S, Fu Z, Hu Q, Wang L, Piao Y. Intracavity hyperthermia in nasopharyngeal cancer: a phase III clinical study. Int J Hyperthermia. 2011;27(2):180-186.
人才培養
近五年來，已培養博士研究生15人、碩士研究生10人、規範化培訓學員20人，注重學術前沿引導與臨床實踐能力相結合，形成系統化、重實踐、可延續的人才培養路徑，有效支持不同階段青年人才的成長與發展。
學術任職
中華醫學會放療分會腫瘤熱療學組組長
中華醫學會腫瘤學分會肺癌專家委員會副主任委員
中國臨床腫瘤學會（CSCO）腫瘤熱療專家委員會主任委員
中國臨床腫瘤學會（CSCO）腦轉移腫瘤專家委員會副主任委員
中國抗癌協會放療專業委員會副主任委員
中國抗癌協會抗癌藥物專業委員會候任主任委員
中國藥理學會腫瘤藥理與化療專業委員會候任主任委員
亞洲腫瘤熱療學會候任主席
國家藥督局藥物評審中心新藥評審專家
浙江省醫學會腫瘤學分會候任主任委員
浙江省抗癌協會放療專業委員會主任委員
浙江省抗癌協會肺癌專業委員會候任主任委員
浙江省抗癌協會副理事長
杭州市抗癌協會理事長
浙江省醫學科學院肺癌研究所所長
浙江省中西醫結合分子腫瘤重點實驗室主任
杭州市轉化醫學研究中心主任
出診時間
周二下午 杭州市腫瘤醫院(市一集團吳山院區)
獎項榮譽
成果多次獲省科技進步二、三等獎、省醫藥衛生科技一等獎、省中醫藥科技二等獎、市科技進步一等獎等。
2004年入選浙江省“151人才工程”第二層次；
2010年入選浙江省“151人才工程”第一層次；
2007年入選浙江省首批衛生高層次創新人才；
先後獲得浙江省“優秀醫生”等榮譽稱號。
